194 related articles for article (PubMed ID: 36341371)
21. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
22. HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins.
Zavareh RB; Spangenberg SH; Woods A; Martínez-Peña F; Lairson LL
Cell Chem Biol; 2021 Feb; 28(2):158-168.e5. PubMed ID: 33113406
[TBL] [Abstract][Full Text] [Related]
23. Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance.
Maiti S; Picard D
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139005
[TBL] [Abstract][Full Text] [Related]
24. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
25. The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep.
Chang C; Tang X; Woodley DT; Chen M; Li W
Cells; 2023 Jan; 12(2):. PubMed ID: 36672211
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System.
Zheng ZG; Zhang X; Liu XX; Jin XX; Dai L; Cheng HM; Jing D; Thu PM; Zhang M; Li H; Zhu J; Liu C; Xue B; Li Y; Chen L; Peng C; Zhu W; Wang L; Liu J; Li HJ; Li P; Xu X
Theranostics; 2019; 9(20):5769-5783. PubMed ID: 31534518
[No Abstract] [Full Text] [Related]
27. LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung.
Barabutis N; Handa V; Dimitropoulou C; Rafikov R; Snead C; Kumar S; Joshi A; Thangjam G; Fulton D; Black SM; Patel V; Catravas JD
Am J Physiol Lung Cell Mol Physiol; 2013 Jun; 304(12):L883-93. PubMed ID: 23585225
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
Isermann T; Schneider KL; Wegwitz F; De Oliveira T; Conradi LC; Volk V; Feuerhake F; Papke B; Stintzing S; Mundt B; Kühnel F; Moll UM; Schulz-Heddergott R
bioRxiv; 2024 Feb; ():. PubMed ID: 38464125
[TBL] [Abstract][Full Text] [Related]
30. Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.
Lu X; Lu X
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188702. PubMed ID: 35227829
[TBL] [Abstract][Full Text] [Related]
31. Proliferation, migration, and resistance to oxidative and thermal stresses of HT1080 cells with knocked out genes encoding Hsp90α and Hsp90β.
Petrenko V; Vrublevskaya V; Bystrova M; Masulis I; Kopylova E; Skarga Y; Zhmurina M; Morenkov O
Biochem Biophys Res Commun; 2023 Sep; 674():62-68. PubMed ID: 37406487
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous Responses and Isoform Compensation the Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer.
Tang X; Chang C; Mosallaei D; Woodley DT; Schönthal AH; Chen M; Li W
Mol Cell Biol; 2022 Feb; 42(2):e0045921. PubMed ID: 34871064
[TBL] [Abstract][Full Text] [Related]
33. Aberrant HSP90 Expression in Lymphocytes and HSP90 Response to Anti-PD-1 Therapy in Lymphoma Patients.
Albakova Z; Mangasarova Y; Albakov A; Nikulina E; Kravchenko S; Sapozhnikov A
Front Immunol; 2022; 13():893137. PubMed ID: 35572591
[TBL] [Abstract][Full Text] [Related]
34. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
35. BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade.
Olson BM; Chaudagar K; Bao R; Saha SS; Hong C; Li M; Rameshbabu S; Chen R; Thomas A; Patnaik A
Mol Cancer Ther; 2023 Jun; 22(6):751-764. PubMed ID: 37014264
[TBL] [Abstract][Full Text] [Related]
36. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
37. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
38. Photothermal therapies to improve immune checkpoint blockade for cancer.
Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
[TBL] [Abstract][Full Text] [Related]
39. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
40. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
